Quick Answer
Tarsus Pharmaceuticals, Inc. reported Stockholders Equity of $343.43 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +53.0% in Stockholders Equity from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$3.10 million | Q2 2019: -$3.92 million | Q3 2019: -$4.60 million | Q1 2020: -$7.96 million | Q2 2020: -$11.04 million | Q3 2020: -$17.83 million | Q1 2021: $183.23 million | Q2 2021: $192.47 million | Q3 2021: $179.14 million | Q1 2022: $149.20 million | Q2 2022: $221.51 million | Q3 2022: $202.63 million | Q1 2023: $173.40 million | Q2 2023: $147.73 million | Q3 2023: $213.66 million | Q1 2024: $275.21 million | Q2 2024: $252.25 million | Q3 2024: $237.48 million | Q1 2025: $342.46 million | Q2 2025: $332.61 million | Q3 2025: $335.08 million.
- Over the full 9 years of available data (2017 to 2025), Tarsus Pharmaceuticals, Inc.'s Stockholders Equity has grown by 780,613.6%.
- Historical annual values: Fiscal year 2025: $343.43 million | Fiscal year 2024: $224.53 million | Fiscal year 2023: $196.99 million | Fiscal year 2022: $192.90 million | Fiscal year 2021: $166.73 million | Fiscal year 2020: $165.98 million | Fiscal year 2019: -$6.01 million | Fiscal year 2018: -$1.35 million | Fiscal year 2017: -$44.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: